Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

The In Vivo Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma

YU-SHAN CHEN, ROU SUN, WEI-LUNG CHEN, YU-CHEN YAU, FEI-TING HSU, JING-GUNG CHUNG, CHIA-JUNG TSAI, CHIA-LING HSIEH, YING-MING CHIU and JIANN-HWA CHEN
In Vivo July 2020, 34 (4) 1789-1796; DOI: https://doi.org/10.21873/invivo.11973
YU-SHAN CHEN
1Department of Radiation Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROU SUN
2Department of Medical Imaging, Taipei Medical University Hospital, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WEI-LUNG CHEN
3Department of Emergency Medicine, Cathay General Hospital, Taipei, Taiwan, R.O.C.
4School of Medicine, Fu Jen Catholic University, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU-CHEN YAU
5Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Lukang, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FEI-TING HSU
6Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JING-GUNG CHUNG
6Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIA-JUNG TSAI
7Department of Medical Imaging and Radiological Sciences, I-Shou University, Kaohsiung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIA-LING HSIEH
8The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, R.O.C.
9TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chsieh2@tmu.edu.tw ymcgreen@yahoo.com.tw D7028@mail.cmuh.org.tw chenjiannhwa@yahoo.com.tw cgh08335@cgh.org.tw
YING-MING CHIU
10Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
11School of Medicine, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chsieh2@tmu.edu.tw ymcgreen@yahoo.com.tw D7028@mail.cmuh.org.tw chenjiannhwa@yahoo.com.tw cgh08335@cgh.org.tw
JIANN-HWA CHEN
12Department of Emergency Medicine, Cathay General Hospital, Taipei, Taiwan, R.O.C.
13School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chsieh2@tmu.edu.tw ymcgreen@yahoo.com.tw D7028@mail.cmuh.org.tw chenjiannhwa@yahoo.com.tw cgh08335@cgh.org.tw
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Radiation (RT) induced ERK/NF-κB in hepatocellular carcinoma (HCC) has been reported in our previous works; it weakens the toxicity of RT or triggers a radioresistance effect. Thus, combining RT with a suitable NF-κB inhibitor may sensitize HCC to RT. Magnolol, a bioactive compound, was known to have anti-inflammatory and anti-tumor functions. Here, we aimed to investigate whether magnolol may enhance anti-HCC efficacy of RT in vivo. Materials and Methods: We established a Hep3B bearing mouse to evaluate the efficacy of the combination treatment of magnolol and RT. Results: Most significantly, tumor volume and tumor weight inhibition was found in the combination group. Tumor immunohistochemistry staining also illustrated the suppression of RT-induced ERK/NF-κB-related proteins expression by magnolol. In addition, intrinsic apoptosis-related proteins, such as caspase-3 and -9, were markedly increased in the combination group. Conclusion: Magnolol may effectively enhance anti-HCC ability of RT by downregulating the expression of ERK/NF-κB-related proteins and increasing the expression of apoptosis-related proteins.

  • Magnolol
  • radiation
  • hepatocellular carcinoma
  • apoptosis

Hepatocellular carcinoma (HCC), the most common type of liver cancer in adults, ranks as the fourth leading cause of cancer-related mortality worldwide (1). Patients with advanced HCC are unsuitable candidates for curative treatment options including surgery, liver transplantation, and percutaneous ablation (2). The low tolerance of whole liver to radiation has restricted application of radiotherapy (RT) for HCC in the past. Recent technology advancements in RT such as intensity-modulated RT (IMRT), image-guided RT (IGRT), hypofractionated radiotherapy (HFRT), and stereotactic body RT (SBRT) can precisely deliver high-dose radiation to HCC while reducing noncancerous liver tissue irradiation (3-5). RT has been shown to provide excellent local control and palliative efficacy in unresectable or metastatic HCC (6).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Tumor growth is suppressed by the combination of magnolol with RT in a Hep3B tumor bearing model. (A) The experimental flow chart of the in vivo study. (B) Tumor growth trend was recorded by calliper every three days. (C) The extracted tumors on day 18 are photographed and are displayed. (D) Whole-body CT image from each treatment group on day 18. (E) The weight of the extracted tumors is measured and quantified. (a1p<0.05 and a2 p<0.01 vs. CTRL; b1 p<0.05 and b2 p<0.01 vs. single treatment)

In addition to RT technology, radiosensitizers that sensitize HCC to radiation have been developing. Natural products such as ellagic acid, curcumin, and mesima have been indicated as potential radiosensitizers to boost anti-HCC efficacy of radiation. Induction of mitochondrial apoptosis, arrest of cell cycle G2/M phase, and inhibition of NF-κB activation have been associated with the radiosensitizing effect of natural products in HCC (7-9). Magnolol, one of major components of Magnolia officinalis, has been shown to trigger apoptosis through death receptor (extrinsic)/mitochondrial (intrinsic) pathways and to down-regulate extracellular signal-regulated kinase (ERK)/NF-κB signaling in HCC in vitro and in vivo (10, 11). Magnolol was also recognized to have an anti-inflammation and anti-tumor potential (12). However, whether magnolol functions as radiosensitizer and enhances anti-HCC efficacy of radiation has not yet been elucidated. Therefore, the main purpose of the present study was to investigate the therapeutic efficacy and possible underlying mechanism of magnolol combined with radiation in HCC in vivo.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

No general toxicity is observed following treatment with the combination of magnolol with RT in Hep3B tumor bearing model. (A) Body weight of each mouse was recorded every three days. (B) Representative liver H&E staining results from each group. (a2 p<0.01 vs. CTRL; b2 p<0.01 vs. single treatment)

Materials and Methods

Cell lines. Hep3B cells were purchased from Bioresource Collection and Research Center (BCRC, Hsinchu, Taiwan). Cells were cultured in DMEM (Dulbecco's Modified Eagle Medium), containing with 10% fetal bovine serum, 1% penicillin and streptomycin and 2 mM L-glutamine (Thermo Fisher Scientific, Fremont, CA, USA) at 37°C in 5% CO2 humidified atmosphere.

Animal experiment. All animal experiments were performed in accordance with the protocols approved by the Animal Care and Use Committee at China Medical University (approval number: CMU IACUC-2019-206). Six-week-old male BALB/cAnN.Cg-Foxn1nu/CrlNarl nude mice were purchased from the National Laboratory Animal Centre (Taipei, Taiwan) and housed in a pathogen-free animal facility. The animals were fed sterilised mouse chow and water. Mice (20-25 g) were subcutaneously injected with Hep3B cells (5×106) on the right leg. When tumor volume reached 80 mm3, mice were randomly separated into 4 groups (n=16), including CTRL group (0.1% DMSO daily gavage treatment), Mag group (75 mg/kg magnolol daily gavage treatment), RT group (once dosage of 6 Gy radiotherapy), and combination therapy. All treatments were initiated at day 0, which is indicated in Figure 1A. Tumor volume was measured every three days and calculated using the following formula: Volume=Height×Weight2×0.523. Computer tomography for tumor size assessment was performed on day 18. Mice were sacrificed on day 18 for further liver pathology and tumor protein expression evaluation. All animal experiments were repeated twice.

Radiation exposure. After anesthesia, mice were irradiated by using clinical linear accelerator (6 MV photons, Elekta Synergy linear accelerator, Crawley, UK). Prescribed dose to gross tumor volume was 6 Gy and 1.0 cm bolus was used to cover tumor for dose build up.

Computer tomography (CT) scanning. After eighteen days of treatment, mice were assessed with CT scan (Mediso Ltd., Budapest, Hungary) to evaluate their tumor size. Hep3B bearing animals were sedated by 1-3% isoflurane during whole-body CT examination. The scanning parameters were as follow: tube energy=55 kVp×145 μA; direction=360°; Voxel size=145×145×145 μM (13).

Immunohistochemistry (IHC) staining. After eighteen days of treatment, mice were sacrificed and tumor tissues were extracted for IHC stain. Formalin-fixed (4%), paraffin-embedded tissues were cut into 5 μm sections and subjected to IHC staining, as described previously (14). The sections were immunohistochemically stained using antibodies against cleaved-caspase-3 (E-AB-30004, Elabscience, Houston, TX, USA), cleaved-caspase-8 (E-AB-22107, Elabscience), cleaved-caspase-9 (10380-1-AP, Proteintech, Rosemont, IL, USA), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E-AB-21303, Elabscience), Phospho-NF-κB p65 (Ser276) (#3037, Cell Signaling Technology, Danvers, MA, USA), Ki-67 (E-AB-63523, Elabscience), C-FLIP (E-AB-16437, Elabscience), and MCL-1 (E-AB-33430, Elabscience). IHC stained sections were then imaged by microscope (Nikon ECLIPSE Ti-U, Tokyo, Japan) at 100´ magnification. Finally, the positive staining result of each protein was quantified by ImageJ software version 1.50 (National Institutes of Health, Bethesda, MD, USA).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Intrinsic apoptosis related proteins are enhanced by the combination treatment with magnolol and RT in Hep3B tumor bearing model. (A) Representative tumor IHC staining results of cleaved-caspase-3, -8 and -9 from each group is displayed. (B) Quantification of the results of each group is presented as a bar chart. (a2 p<0.01 vs. CTRL; b2 p<0.01 vs. single treatment) Scale bars: 100 μm.

Hematoxylin and eosin (H&E) staining. Liver tissue extracted from mice on day 18 was prepared for H&E staining. The fixation, paraffin-embedding and slicing procedure was the same as for IHC staining. Hematoxylin and eosin (H&E) staining was executed by Bio-Check Laboratories Ltd (New Taipei, Taiwan) as previously described (15). H&E stained sections were also photographed by Nikon microscope at 100´ magnification.

Statistical analysis. Excel 2017 was used to analyse data. All data are presented as mean±SD. Statistical significance was evaluated through the conventional Student's t-test and one-way ANOVA. p<0.05 was regarded as statistically significant.

Results

Magnolol markedly enhanced the anti-HCC growth effect of RT. To identify whether magnolol may increase the therapeutic efficacy of RT, we established a Hep3B tumor bearing animal model. The experimental flow chart is displayed in Figure 1A. Mice were randomly separated into four groups, including CTRL, MAG (magnolol 75 mg/kg), RT (6 Gy) and magnolol combined with RT (M+RT), when mice tumor reached 80 mm3. Tumor volume and tumor size were recorded every three days. As shown in Figure 1B, the slowest tumor growth trend was shown in the M+RT group. Tumors extracted from the mice on the final day of therapy were also photographed and were displayed in Figure 1C. The smallest tumor size was found in the M+RT group, which corresponded to the tumor volume results. Furthermore, mice whole-body CT images were taken before sacrifice. Notable tumor growth inhibition was observed in the M+RT group compared to single treatment (Figure 1D). Finally, we also measured the weight of the extracted tumors. The lightest tumor was presented in the M+RT group compared to all single therapies (Figure 1E). Taken together, the above results indicated that magnolol effectively sensitized HCC to RT.

Mice body weight and liver pathology were not affected by magnolol combined with RT in HCC bearing mice. To investigate whether the combination of magnolol with RT may induce general toxicity in mice, we recorded mouse body weight and extracted liver for H&E staining. As shown in Figure 2A, both the M+RT and the magnolol single treatment groups of mice maintained their body weight during the whole treatment process. The non-treated control and the RT group showed marked body weight loss compared to M+RT. In addition, we performed H&E staining on mice liver to investigate liver pathology after treatment. There was no obvious change on liver pathology following the different therapies (Figure 2B). In conclusion, magnolol and RT combination therapy may not induce general toxicity in Hep3B bearing mice.

Magnolol markedly enhanced RT-induced intrinsic apoptosis signalling in HCC bearing mice. Next, we investigated whether apoptosis related mechanisms were affected by the combination of magnolol with RT using IHC staining of the mouse tumor tissue. As indicated in Figure 3A and B, protein expression of the apoptosis marker cleaved caspase-3 was markedly increased 1 to 1.5 times by M+RT compared to single treatments. Furthermore, protein expression of cleaved caspase-9, a recognized intrinsic apoptosis marker, was also augmented by M+RT compared to the single treatment. Similar induction of cleaved caspase-8 protein, an extrinsic apoptosis marker, was found in all treatment groups. Taken together, magnolol may effectively enhance the induction of intrinsic apoptosis by RT.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

RT induced phosphorylation of ERK/NF-κB and expression of their downstream proteins was blocked by magnolol in Hep3B tumor bearing model. (A, C, E) Representative tumor IHC staining results of P-ERK, P-NF-κB, Ki-67, C-FLIP, MCL-1, XIAP, IL-1β and TNF-α from each group. (B, D, F) Quantification of the results of each group is shown as bar chart. (a1 p<0.05 and a2 p<0.01 vs. CTRL; b2 p<0.01 vs. single treatment) Scale bars: 100 μm.

Magnolol diminished RT-activated ERK/NF-κB and its downstream signalling in HCC bearing mice. A previous study has suggested that RT may activate ERK/NF-κB and expression of their downstream proteins in HCC (16). Here, we aimed to evaluate whether magnolol may suppress RT-induced ERK/NF-κB mediated signal transduction. As illustrated in Figure 4A and B, RT-induced expression of phospho-ERK and phospho-NF-κB were diminished by combination of RT with magnolol. The proliferation marker, Ki-67 was effectively reduced in the M+RT group compared to single treatment (Figure 4C and D). Furthermore, NF-κB mediated expression of anti-apoptosis proteins including C-FLIP, MCL-1 and XIAP was markedly reduced by M+RT treatment. NF-κB-mediated expression of inflammation proteins such as IL-1β and TNF-α were also markedly suppressed by the combination of magnolol with RT (Figure 4E and F). These results indicated that magnolol may effectively suppress RT-induced ERK/NF-κB pathway and the expression of the related anti-apoptosis and inflammation proteins.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

The proposed mechanism of the effect of the combination of magnolol with RT. Arrow indicates induction. Magnolol may trigger the apoptosis pathway and suppress ERK/NF-κB related signal transduction.

Magnolol enhanced RT efficacy via the induction of apoptosis signalling and inhibition of ERK/NF-κB mediated pathways in HCC bearing mice. As showed in Figure 5, both RT and magnolol may induce the expression of the extrinsic and intrinsic apoptosis-related proteins, included cleaved-caspase-3, -8 and -9. In addition, the ERK/NF-κB signalling transduction that induced by RT can be mitigated by magnolol. The NF-κB downstream signalling that is involved in anti-apoptosis and inflammation was decreased by magnolol. In summary, magnolol may facilitate RT's anti-HCC potential through triggering apoptosis and inhibiting ERK/NF-κB pathway.

Discussion

In our study, the therapeutic efficacy of the combination of magnolol with radiation (high-energy x-rays) was evaluated by using HCC bearing mice. We found that magnolol was a radiosensitizer that significantly promoted radiation-mediated inhibition of tumor growth in HCC in vivo. Cleaved-caspase-3, -8, and -9 are required for radiation-induced apoptosis through the extrinsic and intrinsic pathways (17). Our findings showed that the combination of magnolol and radiation significantly increased expression of both cleaved-caspase-3 and caspase-9 compared to magnolol or radiation alone treatment (Figure 3). Magnolol may enhance radiation-induced apoptosis through the intrinsic apoptotic pathway in HCC.

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is the key transcription factor which mediates cancer cell radioresistance by regulating the expression of anti-apoptotic genes. Anti-apoptotic proteins C-FLIP, MCL-1, and XIAP limit the anti-cancer efficacy of radiation by inhibiting the extrinsic and intrinsic apoptosis signaling transduction (18, 19). In a previous study, inhibitor of κBα mutant vector(p-IκBαM), a super repressor of NF-κB, not only augmented radiation-induced cytotoxicity but also inhibited expression of radiation-triggered NF-κB-related proteins in HCC (16). The increased expression of proinflammatory cytokines TNF-α and IL-1β as unfavorable prognostic markers was associated with recurrence of HCC (20). QNZ, an inhibitor of NF-κB signaling, has been shown to decrease protein levels of C-FLIP, MCL-1, XIAP, TNF-α, and IL-1 β in HCC in vitro (21, 22). Our data demonstrated that magnolol promoted radiation--decreased phosphorylation of NF-κB, protein levels of C-FLIP, MCL-1, XIAP, TNF-α, and IL-1 β in HCC ex vivo (Figure 4).

ERK, a member of activated protein kinase (MAPK) family, is the downstream component of RAF/mitogen-activated protein/ERK kinase (MEK)/ERK signaling pathway involved in tumor progression (23). ERK has been demonstrated to regulate expression of proliferation, anti-apoptotic, and invasion-related proteins through activation of the NF-κB signaling in HCC (10, 20). Furthermore, radioresistance of cancer cells has been linked to the phosphorylation of ERK (24). Sorafenib, an inhibitor of RAF/MEK/ERK signaling, has been shown to reverse the radiation-induced NF-κB activity and expression of NF-κB-related proteins in HCC (16). Magnolol has been shown to reduce NF-κB activation and expression of NF-κB-related proteins through upregulating dephosphorylation of ERK in HCC in vitro and in vivo (10, 11). In this study, magnolol inhibited radiation-induced ERK phosphorylation in HCC in vivo (Figure 4A).

In conclusion, magnolol is a radiosensitizer that enhances the therapeutic effect of radiation in HCC in vivo. The radiosensitizing effect of magnolol on tumor growth of hepatocellular carcinoma in vivo is mediated through the induction of the intrinsic apoptosis pathway and suppression of NF-κB signaling.

Acknowledgements

This study was funded by Taipei Medical University, Taipei, Taiwan (Grant ID: 107TMU-TMUH-18). We also want to thanks to “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE). This study was also supported by Show Chwan Memorial Hospital, Cathay General Hospital and China Medical University Hospital, respectively. (Grant ID: RD108023, CGH-MR-A10823 and DMR-109-172)

Footnotes

  • Authors' Contributions

    YSC, RS, WLC and YCY performed the experiments. FTH, JGC and CJT prepared the initial version of the paper. CLH, YMC and JHC designed the study, performed the literature review, and prepared the final versions of the paper.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors declare no competing financial interests regarding this study.

  • Received April 9, 2020.
  • Revision received April 15, 2020.
  • Accepted April 17, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Yang JD,
    2. Hainaut P,
    3. Gores GJ,
    4. Amadou A,
    5. Plymoth A,
    6. Roberts LR
    : A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16(10): 589-604, 2019. PMID: 31439937. DOI: 10.1038/s41575-019-0186-y
    OpenUrl
  2. ↵
    1. Forner A,
    2. Hessheimer AJ,
    3. Isabel Real M,
    4. Bruix J
    : Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60(2): 89-98, 2006. PMID: 16860993. DOI: 10.1016/j.critrevonc. 2006.06.001
    OpenUrlCrossRefPubMed
  3. ↵
    1. Nakajima T,
    2. Ninomiya Y,
    3. Nenoi M
    : Radiation-induced reactions in the liver - modulation of radiation effects by lifestyle-related factors. Int J Mol Sci 19(12): 3855, 2018. PMID: 30513990. DOI: 10.3390/ijms19123855
    OpenUrl
    1. Wu CH,
    2. Chen CY,
    3. Yeh CT,
    4. Lin KH
    : Radiosensitization of hepatocellular carcinoma through targeting radio-associated microrna. Int J Mol Sci 21(5), 2020. PMID: 32182776. DOI: 10.3390/ijms21051859
  4. ↵
    1. Hara K,
    2. Takeda A,
    3. Tsurugai Y,
    4. Saigusa Y,
    5. Sanuki N,
    6. Eriguchi T,
    7. Maeda S,
    8. Tanaka K,
    9. Numata K
    : Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: A propensity score analysis. Hepatology 69(6): 2533-2545, 2019. PMID: 30805950. DOI: 10.1002/hep.30591
    OpenUrl
  5. ↵
    1. Chen CP
    : Role of radiotherapy in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol 7(2): 183-190, 2019. PMID: 31293919. DOI: 10.14218/JCTH.2018.00060
    OpenUrl
  6. ↵
    1. Das U,
    2. Biswas S,
    3. Chattopadhyay S,
    4. Chakraborty A,
    5. Dey Sharma R,
    6. Banerji A,
    7. Dey S
    : Radiosensitizing effect of ellagic acid on growth of hepatocellular carcinoma cells: An in vitro study. Sci Rep 7(1): 14043, 2017. PMID: 29070894. DOI: 10.1038/s41598-017-14211-4
    OpenUrl
    1. Hsu FT,
    2. Liu YC,
    3. Liu TT,
    4. Hwang JJ
    : Curcumin sensitizes hepatocellular carcinoma cells to radiation via suppression of radiation-induced nf-kappab activity. Biomed Res Int 2015: 363671, 2015. PMID: 26539482. DOI: 10.1155/2015/363671
    OpenUrl
  7. ↵
    1. Jeong YK,
    2. Oh JY,
    3. Yoo JK,
    4. Lim SH,
    5. Kim EH
    : The biofunctional effects of mesima as a radiosensitizer for hepatocellular carcinoma. Int J Mol Sci 21(3), 2020. PMID: 32013255. DOI: 10.3390/ijms21030871
  8. ↵
    1. Kuan LY,
    2. Chen WL,
    3. Chen JH,
    4. Hsu FT,
    5. Liu TT,
    6. Chen WT,
    7. Wang KL,
    8. Chen WC,
    9. Liu YC,
    10. Wang WS
    : Magnolol induces apoptosis and inhibits ERK-modulated metastatic potential in hepatocellular carcinoma cells. In Vivo 32(6): 1361-1368, 2018. PMID: 30348689. DOI: 10.21873/invivo.11387
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Tsai JJ,
    2. Chen JH,
    3. Chen CH,
    4. Chung JG,
    5. Hsu FT
    : Apoptosis induction and erk/nf-kappab inactivation are associated with magnolol-inhibited tumor progression in hepatocellular carcinoma in vivo. Environ Toxicol 35(2): 167-175, 2020. PMID: 31714653. DOI: 10.1002/tox.22853
    OpenUrl
  10. ↵
    1. Brendan TM,
    2. HURTA ROBERT A. R.
    : Magnolol affects expression of IGF-1 and associated binding proteins in human prostate cancer cells in vitro. Anticancer Res 34(11): 6333-6338, 2014. PMID: 25368232.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Weng MC,
    2. Li MH,
    3. Chung JG,
    4. Liu YC,
    5. Wu JY,
    6. Hsu FT,
    7. Wang HE
    : Apoptosis induction and akt/nf-kappab inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. Biomed Pharmacother 116: 109032, 2019. PMID: 31163381. DOI: 10.1016/j.biopha.2019.109032
    OpenUrl
  12. ↵
    1. Tsai JJ,
    2. Hsu FT,
    3. Pan PJ,
    4. Chen CW,
    5. Kuo YC
    : Amentoflavone enhances the therapeutic efficacy of sorafenib by inhibiting anti-apoptotic potential and potentiating apoptosis in hepatocellular carcinoma in vivo. Anticancer Res 38(4): 2119-2125, 2018. PMID: 29599330. DOI: 10.21873/anticanres.12452
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Hsu LC,
    2. Tu HF,
    3. Hsu FT,
    4. Yueh PF,
    5. Chiang IT
    : Beneficial effect of fluoxetine on anti-tumor progression on hepatocellular carcinoma and non-small cell lung cancer bearing animal model. Biomed Pharmacother 126: 110054, 2020. PMID: 32145588. DOI: 10.1016/j.biopha.2020.110054
    OpenUrl
  14. ↵
    1. Chen JC,
    2. Chuang HY,
    3. Hsu FT,
    4. Chen YC,
    5. Chien YC,
    6. Hwang JJ
    : Sorafenib pretreatment enhances radiotherapy through targeting mek/erk/nf-kappab pathway in human hepatocellular carcinoma-bearing mouse model. Oncotarget 7(51): 85450-85463, 2016. PMID: 27863427. DOI: 10.18632/oncotarget. 13398
    OpenUrl
  15. ↵
    1. Rahmanian N,
    2. Hosseinimehr SJ,
    3. Khalaj A
    : The paradox role of caspase cascade in ionizing radiation therapy. J Biomed Sci 23(1): 88, 2016. PMID: 27923354. DOI: 10.1186/s12929-016-0306-8
    OpenUrl
  16. ↵
    1. Magne N,
    2. Toillon RA,
    3. Bottero V,
    4. Didelot C,
    5. Houtte PV,
    6. Gerard JP,
    7. Peyron JF
    : Nf-kappab modulation and ionizing radiation: Mechanisms and future directions for cancer treatment. Cancer Lett 231(2): 158-168, 2006. PMID: 16399220. DOI: 10.1016/j.canlet.2005.01.022
    OpenUrlCrossRefPubMed
  17. ↵
    1. Trivigno D,
    2. Essmann F,
    3. Huber SM,
    4. Rudner J
    : Deubiquitinase usp9x confers radioresistance through stabilization of mcl-1. Neoplasia 14(10): 893-904, 2012. PMID: 23097624. DOI: 10.1593/neo.12598
    OpenUrlCrossRefPubMed
  18. ↵
    1. Nakazaki H
    : Preoperative and postoperative cytokines in patients with cancer. Cancer 70(3): 709-713, 1992. PMID: 1320454. DOI: 10.1002/1097-0142(19920801)70:3<709::aid-cncr2820700328> 3.0.co;2-o
    OpenUrlCrossRefPubMed
  19. ↵
    1. Tsai JJ,
    2. Pan PJ,
    3. Hsu FT
    : Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of erk/nf-kappab activation in hepatocellular carcinoma cells. Oncol Rep 37(2): 1036-1044, 2017. PMID: 28000898. DOI: 10.3892/or.2016.5328
    OpenUrlCrossRefPubMed
  20. ↵
    1. Liu YC,
    2. Wu RH,
    3. Wang WS
    : Regorafenib diminishes the expression and secretion of angiogenesis and metastasis associated proteins and inhibits cell invasion via nf-κb inactivation in sk-hep1 cells. Oncology letters 14(1): 461-467, 2017. PMID: 28693192. DOI: 10.3892/ol.2017.6142
    OpenUrl
  21. ↵
    1. Zhou K,
    2. Luo X,
    3. Wang Y,
    4. Cao D,
    5. Sun G
    : Microrna-30a suppresses tumor progression by blocking ras/raf/mek/erk signaling pathway in hepatocellular carcinoma. Biomed Pharmacother 93: 1025-1032, 2017. PMID: 28732393. DOI: 10.1016/j.biopha.2017.07.029
    OpenUrl
  22. ↵
    1. Marampon F,
    2. Ciccarelli C,
    3. Zani BM
    : Biological rationale for targeting mek/erk pathways in anti-cancer therapy and to potentiate tumour responses to radiation. Int J Mol Sci 20(10), 2019. PMID: 31126017. DOI: 10.3390/ijms20102530
PreviousNext
Back to top

In this issue

In Vivo: 34 (4)
In Vivo
Vol. 34, Issue 4
July-August 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The In Vivo Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The In Vivo Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma
YU-SHAN CHEN, ROU SUN, WEI-LUNG CHEN, YU-CHEN YAU, FEI-TING HSU, JING-GUNG CHUNG, CHIA-JUNG TSAI, CHIA-LING HSIEH, YING-MING CHIU, JIANN-HWA CHEN
In Vivo Jul 2020, 34 (4) 1789-1796; DOI: 10.21873/invivo.11973

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The In Vivo Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma
YU-SHAN CHEN, ROU SUN, WEI-LUNG CHEN, YU-CHEN YAU, FEI-TING HSU, JING-GUNG CHUNG, CHIA-JUNG TSAI, CHIA-LING HSIEH, YING-MING CHIU, JIANN-HWA CHEN
In Vivo Jul 2020, 34 (4) 1789-1796; DOI: 10.21873/invivo.11973
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Therapeutic Efficacy and Inhibitory Mechanism of Regorafenib Combined With Radiation in Colorectal Cancer
  • Google Scholar

More in this TOC Section

  • Systemic Administration of Lipopolysaccharide from Porphyromonas gingivalis Decreases Neprilysin Expression in the Mouse Hippocampus
  • Monitoring T-Cell Kinetics in the Early Recovery Period of Lung Transplantation Cases by Copy Number Levels of T-Cell Receptor Excision Circle
  • Successful Surgical Outcome of Feline Inductive Odontogenic Tumor in Three Cats
Show more Experimental Studies

Similar Articles

Keywords

  • Magnolol
  • radiation
  • hepatocellular carcinoma
  • apoptosis
In Vivo

© 2023 In Vivo

Powered by HighWire